STAT+: Parasite engineered to treat brain development disorder in mice shows potential in study
The human body works hard to prevent outside substances from entering the brain — which…
Category: STAT+
STAT+: For-profit hospitals are getting a boost from a flood of patients
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money…
STAT+: In a big step for liquid biopsy, FDA approves a blood test for colorectal cancer
The Food and Drug Administration on Monday approved a blood test intended to detect colon…
STAT+: Pharmalittle: We’re reading about Sarepta’s demand to censor a critical video, Roche fast-tracking an obesity pill, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Could cow vaccines help halt the spread of bird flu in U.S. herds? Experts are divided
With the number of U.S. dairy herds infected with H5N1 bird flu rising almost daily,…
STAT+: Sarepta demanded Duchenne patient advocacy group censor video critical of the company
Sarepta Therapeutics demanded a prominent patient advocacy organization censor a video that contained pointed criticism…
.jpg)
STAT+: Disruptions loom for telehealth providers and patients as Congress inches closer to deadline
Around November, Kivo Health, a telehealth provider of pulmonary rehabilitation services, will need to start…
STAT+: Pharmalittle: We’re reading about a thumbs down for an Alzheimer’s drug, Pfizer gene therapy struggles, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: European regulators say Alzheimer’s therapy Leqembi should be rejected
LONDON — European regulators on Friday said that an Alzheimer’s therapy from Eisai and Biogen…
STAT+: How Pfizer’s grand gene therapy ambitions crumbled
A decade ago, Pfizer began investing heavily in gene therapy, bringing in experimental treatments for…
STAT+: Powerful Senate committee demands testimony from CEO of bankrupt Steward hospital chain
Federal lawmakers investigating the Steward Health Care bankruptcy moved on Thursday to compel testimony from…
STAT+: The state pharma’s targeting this election cycle
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: A preview of Neurocrine’s muscarinic drug readout
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
STAT+: Pharmalittle: We’re reading about a Viking obesity drug, Bausch Health’s bankruptcy denial, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Federal regulation of health data and AI expected to get a boost after HHS revamp
A little-known office within the Department of Health and Human Services is getting a shot…
STAT+: How UnitedHealth harnesses its physician empire to squeeze profits out of patients
UnitedHealth Group started out as a small, Minnesota health insurance company and has since morphed…
STAT+: Viking accelerates development of obesity drug that could rival Wegovy, Zepbound
Viking Therapeutics plans to move its injectable obesity treatment into a Phase 3 study faster…
STAT+: Jiankui He, creator of CRISPR-edited children, relocates to a Chinese medical tourism hub
Jiankui He, the Chinese scientist who sparked a global uproar in 2018 when he revealed…
STAT+: Pharmalittle: We’re reading about a CVS deal with Illinois, a Pfizer hemophilia therapy, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Sage suffers pipeline setback with failure of drug to treat essential tremor
Sage Therapeutics said Wednesday that an experimental pill failed to quell involuntary muscle shaking in…
STAT+: Pfizer gene therapy reduced hemophilia bleeds, but questions remain
Pfizer said Wednesday that its gene therapy for hemophilia A successfully reduced patients’ bleeds for…
Robotic aid helped improve balance, gait in children with cerebral palsy
For many kids with cerebral palsy, walking is taxing. They might spend thousands of hours…
Opinion: STAT+: Cell donors are essential for new therapies. They need to be taken care of
Cutting-edge FDA-approved therapies made from human cells are now being used to treat cancer, diabetes,…
STAT+: CVS and its PBM agree to pay $45 million to Illinois for failing to pass drug rebates
CVS Caremark, one of the largest pharmacy benefit managers in the country, agreed to pay…
STAT+: U.S. Patent Office software mistakes extend patent life for drugs and need to be fixed, researchers say
Amid concerns that the pharmaceutical industry abuses the U.S. patent system, a new paper suggests…
STAT+: Pharmalittle: We’re reading about PBM practices, DOJ tussling with Regeneron, and more
Top of the morning to you, and a fine one it is, despite the gray…
STAT+: Medical groups are divided over Biden plan to loosen DEA restrictions on marijuana
WASHINGTON — The Biden administration’s proposal to loosen federal restrictions on marijuana is dividing some…
STAT+: A pricey Gilead HIV drug could be made for dramatically less than the company claims, researchers say
Following the release of widely touted study results for a Gilead Sciences HIV treatment, a…
STAT+: Medicare and Medicaid struggles foreshadow a rocky health insurer earnings season
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow…
STAT+: Pharmalittle: We’re reading about Express Scripts overcharging postal workers, Gilead’s AIDS drug price, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: European Commission reaches deal with Vifor for ‘disparaging’ its only rival in iron deficiency market
Following a two-year probe, the European Commission has formalized a proposal from Vifor Pharma to…
STAT+: Express Scripts overcharged postal workers by $45 million, audit says
Express Scripts, one of the largest pharmacy benefit managers in the country, overcharged U.S. Postal…
STAT+: Pharmalittle: We’re reading about an FDA rare disease innovation hub, fewer U.S. drug shortages, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: FDA investigators have not spoken with patients and others alleging misconduct in MDMA trials
At a contentious advisory committee meeting in June, the Food and Drug Administration announced it…
STAT+: Here come Medicare’s first negotiated drug prices
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: Novartis not ready to admit a $3 billion mistake
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
STAT+: Pharmalittle: We’re reading about Gilead’s CMO leaving, Novartis hedging on a drug, and more
Top of the morning to you, and a fine one it is, despite the gray…
STAT+: Broad Institute, facing end of Microsoft cloud contract, shuffles data science leadership
The Broad Institute of MIT and Harvard is perhaps best known for the trailblazing work…
STAT+: Startup Q Bio raises $27 million to build its own full-body scanner
A prevention-focused co-founded by the head of a Stanford research lab is making an expensive…
STAT+: Q&A: The new CEO of biotech’s top trade group on China, vaccines, and Trump
WASHINGTON — BIO’s new CEO John Crowley is making changes. He’s pivoting the biotechnology industry’s…
STAT+: Novartis hedges on when it might submit myelofibrosis drug for approval
LONDON — A Novartis executive on Thursday said “it’s too early to say” whether the…
STAT+: Elevance tumbles as health insurer warns Medicaid members are using more care
Wall Street’s reaction was swift Wednesday after Elevance Health said that the amount of care…
STAT+: With resignations of top leaders, Cassava Sciences exposes a dark, ugly corner of the Alzheimer’s disease world
Cassava Sciences is imploding — and as it crumbles, a dark, ugly corner of the…
STAT+: Gilead’s chief medical officer to leave as R&D efforts stall
Gilead Sciences’ chief medical officer will leave the company early next year as the drugmaker…
STAT+: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Data privacy startup raises $30 million, to ease health care providers’ regulatory burden
Federal guidance restricting hospital websites’ use of third-party trackers along with the proliferation of direct-to-consumer…
STAT+: A Senate bill was touted as a cure for ‘patent thickets.’ Some say the drug industry watered it down
A clutch of headlines last week suggested the U.S. Senate had achieved a breakthrough in…
.jpg)
STAT+: Why clinical trials for digital therapeutics are getting more rigorous
Faced with widespread skepticism about the value of digital therapies, Swing Therapeutics in early 2022…
STAT+: Cardiovascular startup raises $260 million led by ex-Moderna execs’ new VC fund
Cardurion Pharmaceuticals, a startup that launched seven years ago with shelved cardiovascular drug candidates from…
STAT+: Applesauce lead contamination could not have been prevented, top FDA officials says
CHICAGO – The FDA’s top food regulator contended Tuesday that the agency could not have…